Qelbree - (150 mg ; Extended-Release Capsules)

Generic Name	Viloxazine Hydrochloride	Innovator	SUPERNUS PHARMS
Dosage	150 mg ; Extended-Release Capsules	Branded US Sales	Less Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
********	*** \ *********	*** **, ****	*******	********* ********	*** ****** *** ****
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*********	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events

Qelbree - (100 mg; Extended-Release Capsules)

Generic Name	Viloxazine Hydrochloride	Innovator	SUPERNUS PHARMS
Dosage	100 mg; Extended-Release Capsules	Branded US Sales	Less Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
********	*** \ *********	*** **, ****	*******	********* ********	*** ****** *** ****
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*********	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events

Qelbree - (200 mg; Extended-Release Capsules)

Generic Name	Viloxazine Hydrochloride	Innovator	SUPERNUS PHARMS
Dosage	200 mg; Extended-Release Capsules	Branded US Sales	Less Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
********	*** \ *********	*** **, ****	*******	********* ********	*** ****** *** ****
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*********	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events